Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation

Internal Medicine Journal

Volumn 34, Issue 3, 2004, Pages 98-101

  Szer, J ^a   Durrant, S ^d   Schwarer, A P ^b   Bradstock, K F ^e   Gibson, J ^f   Arthur, C ^g   To, L B ^h   Hughes, T ^h   Raunow, H ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c Ctr for Devmtl Cancer Therapeutics   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Antiviral; Cytomegalovirus; Ganciclovir; Prophylaxis

Indexed keywords

CYCLOSPORIN; GANCICLOVIR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION PREVENTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEROLOGY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 1942441028     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1444-0903.2004.00550.x     Document Type: Article

References (13)

1. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of 10 years experience. Rev Infect Dis 1982; 4: 1119-32.
2. Bowden RA, Slichter SJ, Sayers MH, Mon M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-50.
3. Bowden RA, Sayers MH, Flournoy N, Newton B, Banaji M, Thomas ED. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006-10.
4. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1987; 106: 12-18.
5. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA et al. Acyclovir for prevention of cytomegalovirus and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-75.
6. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991; 324: 1005-11.
7. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-6.
8. Nichols WG, Corey L, Gooley T, Drew WL, Miner R, Huang M et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load and outcomes. Blood 2001; 97: 867-74.
9. Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 765-9.
10. Atkinson K, Arthur C, Bradstock K, Dale B, Downs K, Gibson J et al. Prophylactic ganciclovir is more effective in HLA-identical family member recipients than in more heavily immune-suppressed HLA-identical unrelated marrow transplant recipients. Bone Marrow Transplant 1995; 16: 401-6.
11. Picketty C, Bardin C, Gilquin J, Gairard A, Chast F. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 2000; 6: 117-20.
12. Boeckh M, Zaia JA, Jung D, Skettino S, Chauncey TR, Bowden RA. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 13-19.
13. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-15.